The Merck Group, Amgen, Shionogi and Digital Garage-backed digital cognitive treatment developer will get a Nasdaq Capital Market listing through the deal.
US-based digital therapeutics developer Akili Interactive agreed yesterday to a $1bn reverse merger with special purpose acquisition company Social Capital Suvretta Holdings Corp 1, marking exits for pharmaceutical firms Merck Group, Amgen and Shionogi & Co.
The deal will benefit from $162m in private investment in public equity (PIPE) financing, consisting of $100m from Social Capital and $62m from drug developer PureTech Health, Suvretta Capital Management, Apeiron Investment Group, Temasek, Jazz Venture Partners, Omidyar Technology Ventires and Evidity Health Capital.
…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
